# OnCo record favezelimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/favezelimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "favezelimab" ;
  schema:name "Favezelimab"@en ;
  schema:description "Favezelimab is Merck's LAG-3 antibody, tested with pembrolizumab in phase 3 trials in colorectal cancer and classical Hodgkin lymphoma; the colorectal trial did not succeed."@en ;
  schema:url <https://onco.cc/drugs/favezelimab/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=MK-4280> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Anti-LAG-3 monoclonal antibody, intravenous, also coformulated with pembrolizumab (MK-4280A)" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/lag3-blockade/> ;
  onco:targets <https://onco.cc/targets/lag3/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:trials <https://onco.cc/trials/nct03486873/>, <https://onco.cc/trials/nct04895722/>, <https://onco.cc/trials/nct04626479/>, <https://onco.cc/trials/nct04938817/>, <https://onco.cc/trials/nct04626518/>, <https://onco.cc/trials/nct05845814/> .